Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.

NCT Number	NCT07711002
Lead Sponsor	AstraZeneca
Conditions	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Enrollment	1,330 participants
Start Date	2026-10-01
Primary Completion	2031-06-17 (estimated)
Study Completion	2033-06-14 (estimated)
Updated on ClinicalTrials.gov	2026-07-17